Quantcast

Sum Up The Parts: XBI Could Be Worth $125


Shutterstock photo

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (Symbol: XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $125.42 per unit.

With XBI trading at a recent price near $81.49 per unit, that means that analysts see 53.91% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XBI's underlying holdings with notable upside to their analyst target prices are Rocket Pharmaceuticals Inc (Symbol: RCKT), Alder Biopharmaceuticals Inc (Symbol: ALDR), and FibroGen Inc (Symbol: FGEN). Although RCKT has traded at a recent price of $16.13/share, the average analyst target is 85.99% higher at $30.00/share. Similarly, ALDR has 79.95% upside from the recent share price of $12.04 if the average analyst target price of $21.67/share is reached, and analysts on average are expecting FGEN to reach a target price of $69.00/share, which is 69.62% above the recent price of $40.68. Below is a twelve month price history chart comparing the stock performance of RCKT, ALDR, and FGEN:

RCKT, ALDR, and FGEN Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Biotech ETF XBI $81.49 $125.42 53.91%
Rocket Pharmaceuticals Inc RCKT $16.13 $30.00 85.99%
Alder Biopharmaceuticals Inc ALDR $12.04 $21.67 79.95%
FibroGen Inc FGEN $40.68 $69.00 69.62%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

10 ETFs With Most Upside To Analyst Targets ยป

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Investing , Stocks , ETFs
Referenced Symbols: XBI , RCKT , ALDR , FGEN



More from BNK Invest

Subscribe







BNK Invest
Contributor:

BNK Invest

Market News, Investing












Research Brokers before you trade

Want to trade FX?